LTIP Awards and Issue of Equity

Creo Medical Group plc

("Creo" the "Company" or the "Group")

LTIP Awards and Issue of Equity

Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of surgical endoscopy, announces that it is giving effect to the disclosure made in the Circular dated 4 December 2019, and has as of 18 February 2020, granted the following Directors ("Participants") an interest over 370,000 ordinary shares ("LTIP Shares") of 0.1 pence each in the capital of the Company ("Ordinary Shares"), representing approximately 0.2% of the enlarged issued share capital of the Company, pursuant to the Company's newly established Long Term Incentive Plan ("LTIP").

The Company has made an application for 7,000,000 new Ordinary Shares to be admitted to trading on AIM. These new Ordinary Shares will be held by the Company's Employee Benefit Trust ("EBT") and will be used to satisfy exercises of shares currently under option, as well as for future LTIP awards. The voting rights on these new Ordinary Shares will be exercisable by the trustee of the EBT ("Trustee") at its sole discretion.

The Participant and the Trustee jointly own the beneficial interest of the LTIP Shares. The Participant is entitled to any value above the Hurdle Price of £2.50 per share and the Trustee entitled to all value below the Hurdle Price. The Participant has also been granted an option to acquire the Trustee's beneficial interest in the LTIP shares, which vests three years after the acquisition date (subject to remaining in eligible employment) and the exercise of which is subject to a three-month holding period once vested.

Application will be made for 7,000,000 new Ordinary Shares to be admitted to trading on AIM. It is expected that admission will take place on 21 February 2020. Following the allotment and issue, the Company's issued share capital consists of 157,484,021 Ordinary Shares. The Company does not hold any shares in Treasury, as such the total number of shares in issue with voting rights is 157,484,021.

The above figure of 157,484,021 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Enquiries:

The following notifications are intended to satisfy the Company's obligations under Article 19(3) of EU Regulation No 596/2014 (the Market Abuse Regulation).